Comprehensive profiling of plasma and exosomal microRNAs in medication-related osteonecrosis of the jaw

Sujin Oh1, Minjae Park2, Hyun Hwang3

  • 1Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

Scientific Reports
|October 24, 2025
PubMed

Insights

Circulating microRNAs (miRNAs) show promise as biomarkers for medication-related osteonecrosis of the jaw (MRONJ). Four specific miRNAs (miR-483-5p, miR-92-5p, miR-628-3p, miR-486-5p) were identified in plasma and exosomes, potentially aiding MRONJ diagnosis and treatment.

Area of Science:

  • Biochemistry
  • Genetics
  • Oncology

Background:

  • Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of certain medications.
  • The underlying pathophysiology of MRONJ, particularly the role of circulating microRNAs (miRNAs), is not fully understood.

Purpose of the Study:

  • To investigate plasma miRNA expression profiles in patients with MRONJ compared to healthy controls.
  • To identify potential miRNA biomarkers for MRONJ diagnosis and risk stratification.

Main Methods:

  • A case-control study involving 16 MRONJ patients and 15 healthy controls.
  • Quantitative real-time reverse transcriptase PCR (qPCR) arrays to profile 754 miRNAs in plasma.
  • Individual qPCR assays to validate array results in the full cohort and plasma-derived exosomes.

Main Results:

  • Differential miRNA expression profiles were observed between MRONJ patients and controls.
  • miR-483-5p, miR-92-5p, and miR-486-5p were upregulated, while miR-628-3p was downregulated in MRONJ patients.
  • These four miRNAs showed consistent expression differences in both plasma and exosomes, confirming their potential as MRONJ biomarkers.

Conclusions:

  • Four specific miRNAs (miR-483-5p, miR-92-5p, miR-628-3p, miR-486-5p) were identified as potential plasma biomarkers for MRONJ.
  • These biomarkers may reflect key pathogenic pathways in MRONJ.
  • The identified miRNAs could aid in patient risk stratification and guide future therapeutic interventions for MRONJ.